Patient-centric blood sample collection to enable decentralised clinical trials and improve access to healthcare
This program supports innovations in healthcare by focusing on patient-centric blood sample collection to enable decentralised clinical trials and improve access to healthcare. It aims to develop and validate the necessary infrastructure and logistics for at-home blood collection. The initiative seeks to transform clinical research and patient care by making blood sampling more convenient and less invasive.
Who is Funded
The 'Patient-centric Blood Sample Collection' program targets a broad range of entities within EU member states and associated countries, emphasizing collaborative efforts to advance healthcare innovation. The core objective is to improve patient experience and healthcare access through decentralized clinical trials.
What is Funded
This program specifically funds research and innovation activities focused on developing and validating patient-centric blood collection methods and their integration into healthcare systems. The scope is defined by specific technical and operational requirements, while direct device or assay development is excluded.
Type and Scope of Funding
The funding is provided as a grant, with a maximum amount specified per topic. The program operates under a two-stage application process and requires a significant industry contribution.
Conditions and Requirements
Applicants must adhere to specific conditions regarding proposal submission, consortium formation, financial contributions, and other operational provisions.
Application Procedure
The application process for this call is a two-stage procedure, involving distinct submission phases and evaluation criteria defined by Horizon Europe and IHI JU guidelines.
Legal Basis
This program is established and governed by comprehensive EU regulations and specific documents related to the Innovative Health Initiative Joint Undertaking.
Specific Requirements
This section highlights specific technical and scientific requirements for proposals, including detailed aspects related to the demonstration of concordance, validation of logistics, and regulatory interactions.
Supporting Documents
This section lists various supplementary documents and guides that provide comprehensive information and support for applicants throughout the funding program lifecycle.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
4,500,000 €
Allocated Budget:
4,500,000 €
Open Until:
Ongoing
Award Channel:
Framework Programme Call
Region:
EU member states and other European countries associated with Horizon Europe. At least one participating country must be in Eastern Europe. Participation from legal entities in Russia and Belarus is prohibited.
Sectors:
Healthcare, Medical Technology, Research and Development, Service Sector
Beneficiaries:
Patients, healthcare providers, pharmaceutical industry
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Pilot Testing, Implementation, Service Delivery, Capacity Building
Funding Provider
Program Level:
European Union
Funding Body:
European Commission, Innovative Health Initiative Joint Undertaking
Managed By:
Innovative Health Initiative Joint Undertaking (IHI JU)
Additional Partners:
INTERSPREAD GMBH (dissemination, exploitation and communication), SYNYO GmbH (research activities, concept design, solution development, validation, dissemination, exploitation and coordination support), MINDS & SPARKS GMBH (applied research, development, dissemination & exploitation), DYNAMEDICS S.R.L. (informatics platforms, applications and systems for pharmacology and healthcare, regulatory requirements), Papanikolaou Hospital (research and development for immunotherapy/nanotherapy, preclinical and clinical trials), TECH2MARKET SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (dissemination/communication, exploitation), CONSULTECH TECHNOLOGIEBERATUNG GMBH (project management, application process support), NATIONAL CANCER INSTITUTE (research on basic, translational and clinical levels), Flow Analysis and Simulation Team (Fluid Flow, Hydraulics and Heat Transfer, Magnetohydrodynamics, Bioengineering, Thermal Analysis, Drug delivery, magnetic nanoparticles, glioblastoma multiforme, Industrial Applications and Data Management & Analysis, ML & AI), ARTIFICIAL INTELLIGENCE EXPERT SRL (AI-driven Biomedical Data Science, ethical and human-centric AI), BULGARIAN ASSOCIATION FOR PERSONALIZED MEDICINE (personalized medicine, stakeholder dialogue, education/training, communication), PREVING INVESTMENTS GROUP, S.L. (occupational safety and health, blood analysis, case user/tester), HEMEX Benelux BV (Clinical Development Services, regulatory and quality project across therapeutic areas), NOTITIA DOO ZA SAVJETOVANJE I USLUGE (implementation of EU, scientific and strategic projects, tourism, sustainable development, climate and environment protection, artificial intelligence), TURISTICKA ZAJEDNICA ZAGREBACKE ZUPANIJE (sustainable development, smart tourism, cultural heritage, communication, research, analysis, strategic planning, monitoring, evaluation, quality management), LASER CONSULT MUSZAKI-TUDOMANYOS ES GAZDASAGI TANACSADO KORLATOLT FELELOSSEGU TARSASAG (innovation management, IPR, exploitation, technology and knowledge transfer, market analysis, training and coaching), REPADO LOGISMIKOTECHNIKI-IPIRESIESEREYNAS KAI ANAPTIXIS EPE (Regulated Medical Software Development & Regulatory Affairs), HEMEX AG (Clinical Development Services), Humaniti AI Solututions EOOD (ethical and human-centric AI), METTU UNIVERSITY (research)
Website: